Pathology of presynaptic proteins in Alzheimer's disease: more than simple loss of terminals
Abstract
Synaptic pathology is receiving increased attention in the study of the pathophysiology of Alzheimer's disease. A review of the literature on synaptic pathology in Alzheimer's disease was undertaken, focused on five areas. First, concerning the molecular substrates of presynaptic terminal changes, not all proteins are equally affected. Second, all brain regions in Alzheimer's disease do not show equivalent presynaptic protein pathology, hippocampus tended to be most affected. Third, relationships between presynaptic and neurofibrillary tangle pathology tended to be stronger than relationships with plaques. Fourth, broadly speaking, more severe cognitive impairment was associated with more severe presynaptic pathology. Finally, the relationship of presynaptic pathology and stage of illness appeared complex, with some reports of increased presynaptic proteins in earlier phases of illness, but consistent decreases in later phases. Detailed studies of presynaptic pathology in transgenic mouse models related to Alzheimer's disease may provide important insights concerning these observations.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Reduction of SNAP-25 has been observed in age-related dementia including AD.
“We focused our attention on SNAP-25 as reduction of SNAP-25 has been observed in age-related dementia including AD (75)(76)(77).”
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 55 · Cited by 135
- Authors
- Honer, W.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Honer, W
- ORCID
- Honer, W
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2003-12
- Volume
- 24
- Issue
- 8
- Pages
- 1047-1062
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W2040793789
- Cited by
- 135
- References
- 55
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 3 · 2021: 2 · 2020: 6 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 8 · 2015: 9 · 2014: 7 · 2013: 3 · 2012: 6
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG017917, R01 AG 17917-01A1)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, presynaptic proteins, synaptic pathology, presynaptic terminals, neurofibrillary tangles, amyloid plaques, hippocampus, cognitive impairment, disease stage, transgenic mouse model
- MeSH terms
- Alzheimer Disease, Animals, Brain, Cognition Disorders, Disease Models, Animal, Humans, Nerve Tissue Proteins, Neurofibrillary Tangles, Presynaptic Terminals, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review